Certainly, the panellists were very sensitive to these costs. To be clear, their intent was to cover everyone but not to cover everything. That's where the role of an evidence-based national formulary is essential, to identify those medicines that are deemed to be both effective in health terms but also cost-effective as well.
Nevertheless, I think it was striking to realize that Canada continues to spend more as a country per capita to meet the pharmaceutical needs of its population than any other OECD country, barring the U.S. and, as my colleague has pointed out, Switzerland.